323008 SE Case Studies in Drug Discovery and Preclinical Drug Development - MPS7 (2023S)

(2 Courses)

5.00 ECTS (1.00 SWS), SPL 32 - Pharmazie

Prüfungsimmanente Lehrveranstaltung

Moodle

Details

Sprache: Englisch

Lehrende

Termine (iCal) - nächster Termin ist mit N markiert

Dates that are missing above (See Moodle for the schedule for each case study):
1st day of the course: Tuesday 02.05.2023 09.00-11.00 Web-based - all Case Studies
Wednesday 03.05.2023 16.00 - 18.00 Web-based (Case Study 1)
Friday 05.05.2023 14.00 - 16.00 Web-based (Case Study 3)
Monday 15.05.2023 13.00 - 15.00 Web-based (Case Study 3)
Thursday 18.05.2023 16.00 - 18.00 Web-based (Case Study 1)

    
    Freitag
    05.05.
    09:00 - 11:00
    Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
    
    Dienstag
    16.05.
    09:00 - 11:00
    Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
    
    Mittwoch
    31.05.
    09:00 - 11:30
    Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
    
    Montag
    05.06.
    14:00 - 16:30
    Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
    
    Dienstag
    06.06.
    15:00 - 17:30
    Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II

Information

Ziele, Inhalte und Methode der Lehrveranstaltung

Students will work in small teams on case studies to conceptualise concrete drug development project proposals, discuss the case study topics and revise their proposals with the supervisors. The case study will involve a real project conducted in industry. The outcomes from the industry research project will be revealed in the final lecture. The course will consist of Introduction to the course, two lectures, 3 assignments, and 3 feedback/discussion teaching sessions.

Art der Leistungskontrolle und erlaubte Hilfsmittel

Students must attend all sessions and actively participate in the discussion, complete and submit all of the assignments on time. They are expected to incorporate feedback and discussion outcomes into their revised final project proposal that is due before the last day of class.

Mindestanforderungen und Beurteilungsmaßstab

Enrollment in the Master of Drug Discovery and Development program. Successful completion of MPS1 in the Master of Drug Discovery and Development program. Course attendance; completion of assignments including revisions from feedback sessions to be submitted to instructors for evaluation. Final presentation to be submitted and given on last day of course and final revised proposal to be submitted to instructors.

Prüfungsstoff

Team presentation of the finalized project proposal (each team member must present)
Submission of the finalized research proposal and presentation slide deck.

Literatur

To be given in class

Zuordnung im Vorlesungsverzeichnis

MPS7 Case Studies in Drug Discovery und Preclinical Drug Development (5 ECTS)

Master Drug Discovery and Development (606)

Letzte Änderung: Do 26.01.2023 11:50